eligibility_summary
Eligible: patients with DLBCL. Cohort 1: unfit/frail—age ≥80, or <80 with comorbidities and unable to tolerate standard-dose CHOP per investigator. Cohort 2: DLBCL not meeting unfit/frail criteria. Cohort 3: relapsed/refractory DLBCL. Exclude: current/planned participation in another interventional trial, or any reason deemed unsuitable by the investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Prospective, observational registry in China assessing real‑world effectiveness/safety of polatuzumab vedotin in adults with DLBCL (untreated unfit/frail, other untreated, and relapsed/refractory cohorts). Drug/intervention: Polatuzumab vedotin (POLIVY) – an antibody–drug conjugate (humanized anti‑CD79b IgG1) linked to the cytotoxic payload MMAE, a microtubule inhibitor. Mechanism of action: Binds CD79b on B cells, is internalized, releases MMAE intracellularly, disrupting microtubules, causing mitotic arrest and apoptosis of malignant B cells. Cells/pathways targeted: CD79b‑positive mature and malignant B cells in DLBCL, targets the B‑cell receptor (via CD79b) and microtubule dynamics within tumor cells.